Praxis Precision Medicines (PRAX) Non-Current Deffered Revenue (2022 - 2024)
Praxis Precision Medicines (PRAX) posted quarterly Non-Current Deffered Revenue of $293000.0 for Q3 2024, down 80.67% year-over-year from $1.5 million in Q4 2023, and down 50.17% quarter-over-quarter from $588000.0 in Q2 2024.
Praxis Precision Medicines (PRAX) Non-Current Deffered Revenue (2022 - 2024) Analysis & Trends
Praxis Precision Medicines' Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $293000.0 for Q3 2024.
- In Q3 2024, Non-Current Deffered Revenue fell 80.67% year-over-year to $293000.0; the TTM figure through Sep 2024 stood at $293000.0 (down 80.67% YoY), while the FY2023 annual figure was $1.2 million, down 46.79% from the prior year.
- Non-Current Deffered Revenue for Q3 2024 stood at $293000.0, down from $588000.0 in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $2.2 million in Q4 2022, with the low at $293000.0 in Q3 2024.
- The 3-year median for Non-Current Deffered Revenue is $1.3 million (2023), against an average of $1.2 million.
- The sharpest annual moves came in 2023 and 2024: Non-Current Deffered Revenue slumped 46.79% in 2023, then slumped 80.67% in 2024.
- Praxis Precision Medicines' Non-Current Deffered Revenue stood at $2.2 million in 2022, then slumped by 46.79% to $1.2 million in 2023, then tumbled by 74.76% to $293000.0 in 2024.
- Business Quant data shows PRAX's Non-Current Deffered Revenue at $293000.0 in Q3 2024, $588000.0 in Q2 2024, and $866000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.10 Bn | 131.24 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.66 Bn | 76.67 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.59 Bn | 59.40 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.02 Bn | 54.88 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.64 Bn | 36.55 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.90 Bn | 28.59 Bn | 992.69 Mn | - |
| 7 | Royalty Pharma | 27.38 Bn | 26.55 Bn | - | - |
| 8 | BioNTech SE | 27.36 Bn | 8.97 Bn | 668.28 Mn | - |
| 9 | Insmed | 26.66 Bn | 25.50 Bn | 358.27 Mn | - |
| 10 | Praxis Precision Medicines | 10.86 Bn | 10.10 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 293,000.00 |
| Jun 30, 2024 | 588,000.00 |
| Mar 31, 2024 | 866,000.00 |
| Dec 31, 2023 | 1.16 Mn |
| Sep 30, 2023 | 1.52 Mn |
| Jun 30, 2023 | 1.50 Mn |
| Mar 31, 2023 | 1.77 Mn |
| Dec 31, 2022 | 2.18 Mn |